Chirila C, Nuamah I, Woodruff K. Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials. Curr Med Res Opin. 2017 Jun;33(6):1083-90. doi: 10.1080/03007995.2017.1300144
Muser E, Benson C, Chirila C, Graham J, Woodruff K. Resource use and cost in a randomized, non-inferiority trial of paliperidone palmitate 3 versus 1-month formulations in patients with schizophrenia. Poster presented at the 2016 American Psychiatric Association Annual Meeting; May 14, 2016. Atlanta, GA.
Woodruff K, Chirila C, Zheng Q, Van Impe K, Nuamah I. Healthcare resource use of paliperidone palmitate 3-month injection vs. paliperidone palmitate 1-month injection: an analysis of phase III clinical trial hospital data. Poster presented at the 24th European Congress of Psychiatry; March 15, 2016. Madrid, Spain.
Benson C, Chirila C, Graham J, Radder C, Zheng Q, Muser E, Woodruff K. Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.